NASDAQ:IKT | Cash Flow Statement | Inhibikase Therapeutics, Inc.

Complete source-backed cash-flow history.

Available history
2020-03-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$19.59M
2026-03-31-$16.38M-$12.06M$0.00-$80.48M$2.9M
2025-12-31-$12.73M-$7.52M$0.00-$98,847.00$108.57M
2025-09-30-$11.93M
2025-06-30-$9.92M
2025-03-31-$13.68M-$4.1M$13,399.00$21.05M$0.00
2024-12-31-$12.13M-$5.35M$0.00-$38.76M$99.68M
2024-09-30-$5.78M
2024-06-30-$4.96M
2024-03-31-$4.65M-$3.87M$0.00-$3.31M$366,999.00
2023-12-31-$4.18M-$3.44M$0.00-$2.12M-$138,104.00
2023-09-30-$4.6M
2023-06-30-$5.78M
2023-03-31-$4.48M-$5.97M-$5.84M$8.58M
2022-12-31-$4.28M-$3.56M$0.00$4.96M$0.00
2022-09-30-$4.49M
2022-06-30-$4.64M
2022-03-31-$4.64M-$3.93M$0.00-$204,769.00
2021-12-31-$5.04M-$4.1M$0.00$0.00$0.00
2021-09-30-$4.47M
2021-06-30-$2.64M
2021-03-31-$2.64M-$3.93M-$409,662.00
2020-12-31-$1.21M-$946,528.00$14.88M
2020-09-30-$670,599.00
2020-06-30-$421,869.00
2020-03-31-$547,440.00-$255,432.00$250,120.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$48.26M-$27.79M$13,399.00$2.05M$108.46M
2024-12-31-$27.52M-$19.15M$0.00-$37M$103.48M
2023-12-31-$19.03M-$18.09M$14,238.00$11.66M$8.41M
2022-12-31-$18.05M-$17.35M$243,255.00-$16.01M-$204,769.00
2021-12-31-$14.79M-$14.3M$0.00$0.00$41.09M
2020-12-31-$2.85M-$1.13M$15.06M